Refile: UPDATE 1-Catalent stockholders approve deal with Novo Holdings

Catalent

29/05/2024 14:30

(Corrects typo in first paragraph)
       May 29 (Reuters) - Catalent  CTLT.N  said on Wednesday
its stockholders have voted to approve its buyout deal with Novo
Holdings, the parent company of Novo Nordisk  NOVOb.CO .
    In February, Novo Holdings had agreed to buy the contract
drug manufacturer for $16.5 billion to boost the output of its
blockbuster obesity drug Wegovy.
    Stockholders voted to approve the transaction with 99.2% of
ballots cast in favor of the proposed deal, the company said.
    Catalent reiterated the deal is expected to close towards
the end of 2024.
    Novo Holdings is the investment arm of Novo Nordisk's
controlling shareholder, the Novo Nordisk Foundation.

 (Reporting by Sriparna Roy in Bengaluru; Editing by Vijay
Kishore)
 ((Sriparna.Roy@thomsonreuters.com;))